Comparison of propaten heparin-bonded vascular graft with distal anastomotic patch versus autogenous saphenous vein graft in tibial artery bypass

Kaisar et al. 20181

Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA

Primary patency of GORE® PROPATEN® Vascular Graft

N=62
1 year 85%
2 years 71%
3 years 64%
4 years 57%

 

 

Patient characteristics*

Characteristic N %
Rutherford classification  
2 1 2%
3 20 32%
4 15 24%
5 18 29%
6 8 13%
Bypass Indication  
Claudication 10 16%
Rest pain 23 37%
Tissue loss 29 47%
Hypertension 46 74%
Diabetes 32 52%
Renal failure 9 15%
Distal anastomotic vessel  
TP trunk 9 15%
Anterior tibial 14 23%
Posterior tibial 22 36%
Peroneal 17 27%

Study details

  • Retrospective, non-randomized, single-center analysis of prospectively collected data
  • All GORE® PROPATEN® Vascular Graft bypasses utilized a distal patch using either autologous vein (58%) or bovine pericardium (42%)
  • All grafts were 6 mm diameter
  • Wound care techniques included aggressive wound debridement, negative-pressure wound closure, and intravenous antibiotics
  • Compared to autologous vein, patients receiving a GORE® PROPATEN® Vascular Graft experienced a shorter operative time and length of hospital stay, although the difference did not reach a statistical significance
  • No statistically significant difference in primary patency, secondary patency, or limb salvage between patients receiving autologous vein and GORE® PROPATEN® Vascular Graft at four years

[GORE® PROPATEN® Vascular Grafts] with distal anastomotic patch have similar clinical outcomes compared to the saphenous vein graft in tibial artery bypass. Our data support the use of [GORE® PROPATEN® Vascular Graft] with distal anastomotic patch as a viable conduit of choice in patients undergoing tibial artery bypass. – J Kaisar

*GORE® PROPATEN® Vascular Graft group

1. Kaisar J, Chen A, Cheung M, Kfoury E, Bechara C, Lin P. Comparison of propaten heparin-bonded vascular graft with distal anastomotic patch versus autogenous saphenous vein graft in tibial artery bypass. Vascular. 2018;26(2):117-125.

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.